Loading…
Dermata Therapeutics, Inc. is projected to rise to $1.46 by 2027, a +9% move from its current price of $1.34. DRMA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.29 | $1.34 | $1.39 | +0.08% |
| Jul 14 | $1.27 | $1.34 | $1.42 | +0.16% |
| Jul 15 | $1.26 | $1.34 | $1.44 | +0.24% |
| Jul 16 | $1.24 | $1.34 | $1.45 | +0.31% |
| Jul 17 | $1.23 | $1.35 | $1.47 | +0.39% |
| Jul 18 | $1.22 | $1.35 | $1.48 | +0.47% |
| Jul 19 | $1.22 | $1.35 | $1.49 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.22 | $1.35 | $1.49 | +0.55% |
| Week 2 | $1.17 | $1.35 | $1.57 | +1.10% |
| Week 3 | $1.14 | $1.36 | $1.63 | +1.66% |
| Week 4 | $1.12 | $1.37 | $1.68 | +2.22% |
| Week 5 | $1.09 | $1.38 | $1.73 | +2.78% |
| Week 6 | $1.08 | $1.38 | $1.78 | +3.34% |
| Week 7 | $1.06 | $1.39 | $1.83 | +3.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Dermata Therapeutics, Inc. is a healthcare company focused on the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics, Inc. (DRMA) is a healthcare stock trading at $1.41 with a market capitalization of $5.67M. It ranks 5297 by market capitalization among listed assets.
The near-term price outlook is modest, with a 30-day range of $1.07 to $1.86 and a bullish longer-term trajectory suggested by the annual forecast series. The forecast projects gradual upside over time, with averages climbing from $1.41 in 2026 toward higher levels later in the decade and into the 2030s and beyond.
In the multi-year view, the averages rise to $2.23 by 2030 and reach $6.63 by 2050, with corresponding ROIs of 58.3% and 370.1% respectively, signaling a bullish long-run outlook amid ongoing volatility.
A major floor 20.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.7% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 17.2% above — clearing it would confirm fresh momentum.
Key DRMA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DRMA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.37 | Sell | $1.35 | Sell |
| MA 10 | $1.34 | Sell | $1.33 | Buy |
| MA 20 | $1.28 | Buy | $1.30 | Buy |
| MA 50 | $1.27 | Buy | $1.30 | Buy |
| MA 100 | $1.28 | Buy | $1.53 | Sell |
| MA 200 | $2.15 | Sell | $3.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.37 | Neutral |
| Stoch RSI (14) | 58.95 | Neutral |
| CCI (20) | 58.88 | Neutral |
| Williams %R (14) | -29.17 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 8.94 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 70.83 | Neutral |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 60.11 | Neutral |
| Momentum (10) | 0.17 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 1.38 | Sell |
| ADX (14) | 11.17 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day picture shows a range from $1.07 to $1.86. RSI(14) is 60, with the price trading near the 50-day view and below the 200-day view.
The 50-day simple moving average sits at $1.26, while the 200-day simple moving average is at $2.21. Support is at $1.17 and resistance at $1.41, framing a near-term trading range around the current price of $1.41.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.14 | $1.34 | $1.98 | 0% | Neutral | |
| $1.12 | $1.46 | $2.05 | +9% | Neutral | |
| $1.34 | $1.82 | $2.68 | +36% | Bullish | |
| $1.48 | $2.08 | $3.18 | +55% | Bullish | |
| $1.43 | $2.08 | $3.29 | +56% | Bullish | |
| $1.33 | $1.99 | $3.23 | +49% | Bullish | |
| $1.19 | $1.84 | $3.05 | +37% | Bullish | |
| $1.25 | $1.98 | $3.36 | +48% | Bullish | |
| $1.40 | $2.27 | $3.94 | +69% | Bullish | |
| $1.60 | $2.65 | $4.68 | +98% | Bullish | |
| $1.39 | $2.57 | $4.92 | +92% | Bullish | |
| $2.75 | $6.10 | $13.05 | +355% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.14 | $1.34 | $1.57 | +0.00% |
| August 2026 | $1.14 | $1.36 | $1.68 | +1.74% |
| September 2026 | $1.19 | $1.44 | $1.80 | +5.57% |
| October 2026 | $1.17 | $1.42 | $1.80 | -1.34% |
| November 2026 | $1.17 | $1.43 | $1.84 | +0.94% |
| December 2026 | $1.23 | $1.52 | $1.98 | +6.29% |
Click any year to see its month-by-month DRMA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Dermata Therapeutics, Inc.'s 2026 outlook centres on $1.34, within a $1.14 to $1.98 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DRMA could reach as high as $2.05, with a base case around $1.46 and support toward $1.12 — roughly +9% from $1.34. Price action looks broadly range-bound.
Expect DRMA to range from $1.34 to $2.68 through 2028. The $1.82 average target implies a +36% move from current prices. That is up +25% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The DRMA price prediction for 2029 points to an average of $2.08 (low $1.48, high $3.18) — a potential gain of +55% on today's $1.34. Momentum favours further upside here.
In 2030, DRMA is projected to trade between $1.43 and $3.29, averaging $2.08 — a potential gain of +56% from today's $1.34. That is up 0% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Dermata Therapeutics, Inc.'s 2031 outlook centres on $1.99, within a $1.33 to $3.23 range. That is -4% versus the projected 2030 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2032, DRMA could reach as high as $3.05, with a base case around $1.84 and support toward $1.19 — roughly +37% from $1.34. Buyers look set to stay in control over this stretch.
Expect DRMA to range from $1.25 to $3.36 through 2033. The $1.98 average target implies a +48% move from current prices. That is up +8% on the projected 2032 average. Momentum favours further upside here.
The DRMA price prediction for 2034 points to an average of $2.27 (low $1.40, high $3.94) — a potential gain of +69% on today's $1.34. Buyers look set to stay in control over this stretch.
In 2035, DRMA is projected to trade between $1.60 and $4.68, averaging $2.65 — a potential gain of +98% from today's $1.34. That is up +17% on the projected 2034 average. Momentum favours further upside here.
Dermata Therapeutics, Inc.'s 2040 outlook centres on $2.57, within a $1.39 to $4.92 range. That is -3% versus the projected 2035 average. That marks a +92% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DRMA could reach as high as $13.05, with a base case around $6.10 and support toward $2.75 — roughly +355% from $1.34. Momentum favours further upside here.
Investing $1,000 in DRMA today (≈ 746.268657 DRMA) could be worth
$4,552.3
+$3,552.3 (+355%) by 2050 · US Dollar
Based on the average projected DRMA price of $6.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DRMAwould be worth at today's price.
$1,000 invested in DRMA on Jul 10, 2025 (≈ 138.888893 DRMA) would be worth
$186.11
-$813.89 (-81.4%) today · 0.19× · US Dollar
Based on a DRMA entry price of $7.2 vs. today's $1.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.34 | $1,000 | -0.0% |
| 1 month ago | $1.19 | $1,126.05 | +12.6% |
| 3 months ago | $1.22 | $1,098.36 | +9.8% |
| 6 months ago | $1.82 | $736.26 | -26.4% |
| 1 year ago | $7.2 | $186.11 | -81.4% |
| All time (4.9y) ago | $12,456 | $0.11 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DRMA forecast.
Our base-case forecast reaches $2.70 around 2050.
Implied market cap at $2.70: $10.86M
The multi-year forecast paints a bullish long-run path for Dermata Therapeutics, Inc. by year. For 2030 the average price is $2.23 with a forecast ROI of 58.3% and a bullish sentiment. The range for 2030 is $1.50 to $3.60.
In 2040 the average price rises to $2.74 with a forecast ROI of 94.3% and a bullish sentiment, with a range from $1.41 to $5.40.
By 2050 the average price is projected at $6.63 with a forecast ROI of 370.1% and a bullish sentiment, and a max price of $14.67. Earlier years show a mix ofNeutral to bullish signals, with notable growth realized from 2028 onward (avg $1.97 in 2028, ROI 39.5%; 2029 avg $2.26, ROI 60.6%; 2031 avg $2.13, ROI 51.4%; 2035 avg $2.87, ROI 103.6%). The forecast reflects ongoing volatility (annualized volatility 80%) and the potential for substantial upside in the long run, though these are estimates, not guarantees.
Tap a question to reveal the answer.
2030: min $1.50, avg $2.23, max $3.60, ROI 58.3%, sentiment BULLISH.
The forecast shows neutral in 2026 and 2027, turning bullish from 2028 onward. Projected ROIs reach 58.3% by 2030, 94.3% by 2040, and 370.1% by 2050, but these are estimates, not guarantees, and the asset exhibits notable volatility (80%).
Yes, the 2040 forecast has a max of $5.40, with a 2040 average of $2.74 and a 2040 ROI of 94.3%.
Current price is $1.41 and market capitalization is $5.67M.
The 30-day range is $1.07 to $1.86. RSI(14) is 60; SMA50 is $1.26; SMA200 is $2.21. Support is $1.17 and resistance is $1.41.
Dermata Therapeutics, Inc. Community Discussion
0Share your Dermata Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.